CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML) Meeting Abstract
| Authors: | Lancet, J. E.; Cortes, J. E.; Kovacsovics, T.; Hogge, D.; Kolitz, J. E.; Tallman, M. S.; Chiarella, M.; Louie, A. C.; Feldman, E. J. |
| Abstract Title: | CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML) |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-05-20 |
| Language: | English |
| ACCESSION: | WOS:000208880302026 |
| DOI: | 10.1200/jco.2011.29.15_suppl.6519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 6519 -- Source: Wos |
